Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, MabThe
KYV101-007
Phase 2 small_molecule active
Quick answer
Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, MabThe for Primary or Secondary Progressive Multiple Sclerosis is a Phase 2 program (small_molecule) at Kyverna Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kyverna Therapeutics
- Indication
- Primary or Secondary Progressive Multiple Sclerosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active